Compare Gilead Sciences, Inc. (GILD) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Wayfair Inc — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.09B), while Wayfair Inc trades at $105.14 (market cap $14.31B). The key difference: Gilead Sciences, Inc. is far larger — about 12.7× Wayfair Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Wayfair Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Wayfair Inc for 8 Days on average.
| GILD | W | |
|---|---|---|
Market Cap | $182.09B | $14.31B |
Volume | 4,960,247 | 1,595,934 |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $119.05 |
52-Week Low | $116.74 | $57.40 |
Typical Hold Time | 111 Days | 8 Days |
Enterprise Value | $205.15B | $16.64B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
Wayfair (W) trades at $104.47, down 0.93% with a bullish technical outlook. The company shows mixed fundamentals with $12.46B revenue but negative net margins, while analysts maintain a buy consensus with a $114.06 price target. Recent developments include store expansion and upcoming Q3 earnings.
The stock presents upside potential from analyst targets and operational cash flow growth, but faces risks from persistent losses and high debt. Key catalysts include Q3 earnings on November 4, 2026, and execution of the new brand platform amid competitive retail pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
